🦟Exciting News! Registrations are now open for the Malaria MOOC! 👉 Enroll Now : fun-mooc.fr/en/courses/mal… The MOOC provides an overview of malaria today, from the cellular biology of the parasite to treatments, from immune response to control and elimination strategies.

"Malaria is as old as Egyptian civilization itself, but the disease that plagued pharaohs now belongs to its history and not its future." - Tedros Adhanom Ghebreyesus World Health Organization (WHO) YES! Congratulations go out to 🇪🇬 EGYPT on being certified #ZeroMalaria 👏

Thank you for inviting me to #ISV2024. An honour to give this plenary talk, and what a fantastic first day of #vaccine research talks and posters!

Big congrats to Amy Kristine Bei, Laty Gaye Thiam and their team on the first analysis of #RH5 blood-stage #malaria human #mAbs against P. falciparum clinical isolates in Senegal. Encouraging for strain-transcendence. Check out their great paper npj Journals below👇

PREVENTION: The Invisible Future of Health - Sir Andrew Pollard The 17th Unither Baruch Blumberg Lecture 4:30pm Wednesday 13th November 2024 Oxford University Museum of Natural History Parks Road, Oxford OX1 3PW

🎙️ISV Global Webinar Series 👉6th December 2024  07:00 (PST) | 1:00 (EST) | 17:00 (South Africa) | 20:30 (IST) Title: "Vaccines against Outbreak Pathogens - what next?" by Dr Teresa Lambe The Lambe Lab University of Oxford 👉Join us: zoom.us/j/92532088081#…

The French Riviera of the East beckons!! Come, join us for the 9th ICPvR, hosted by ICMR-VCRC.

Ahead of his retirement lecture today, we celebrate the extraordinary career of Professor Sir Brian Greenwood, a pioneer in global health and malaria research. Read more about his remarkable contributions👇 bit.ly/3AXUrxH

🦟 #Malaria remains a major global health challenge, with rising deaths and drug resistance adding urgency to the fight. 🌍🤝 Join us for the 21st edition of #EMBLMalaria as we strengthen partnerships, share insights, and drive innovations to combat malaria's toll and advance

NEWS: First vaccine against blood-stage malaria is well-tolerated and offers effective protection The study showed that the new vaccine (RH5.1/Matrix-MTM) was well tolerated with no safety concerns, working by reducing the parasite level in the blood. medsci.ox.ac.uk/news/first-vac…

📢 Sign up for BioMalPar XXI and join us in this crucial endeavour to understand the biology of the malaria parasite and to advance global health 🌍⚕️#EMBLMalaria 👉🏻 s.embl.org/bmp25-01-x Topics 🦟 Epidemiology 🦟 Vaccines & immunity 🦟 Vector & transmission 🦟 Molecular &

Our group's new BIO-006 clinical trial on #vivax #malaria is recruiting now in Oxford. The first trial in our OptiVivax consortium. Aiming to assess relapsing malaria infection - check out the link below 👇

#OptiViVax launches a first-in-kind clinical trial, BIO-006, with the Oxford Vaccine Group to investigate relapsing malaria infection caused by Plasmodium vivax. Find out more here: optivivax.web.ox.ac.uk/article/draper… Kavli Institute for Nanoscience Discovery, Oxford Medical Sciences University of Oxford The Kavli Foundation Department of Paediatrics

Great podcast by Andrew Duncan explaining our latest P. vivax malaria challenge clinical trial. Part of the #OptiVivax Consortium working with the Oxford Vaccine Group and Kavli Institute for Nanoscience Discovery, Oxford ovg.ox.ac.uk/studies/bio006 Department of Paediatrics Medical Sciences University of Oxford The Kavli Foundation

Thanks to global immunisation efforts, an estimated 154 million lives have been saved over the past 50 years 🌎 🤝 That’s equivalent to 6 lives every minute. #CelebrateVaccines

Exciting data from a human malaria re-challenge model deciphering how humans become immunologically tolerant to falciparum #malaria. Big thanks to fantastic collaborators Malaria Immunology.